ARTIFACT SHEET

Enter artifact number below. Artifact number is application number + artifact type code (see list below) + sequential letter (A, B, C...). The first artifact folder for an artifact type receives the letter A, the second B, etc.. Examples: 59123456PA, 59123456PB, 59123456ZA, 59123456ZB

Indica indivi	te quantity of a single type of artifact received but not scanned. Create dual artifact folder/box and artifact number for each Artifact Type.
	CD(s) containing computer program listing Doc Code: Computer Artifact Type Code: P
	Stapled Set(s) of Extra Color Drawings/Photographs Doc Code: Artifact Type Code: C
	CD(s) containing pages of specification and/or sequence listing Artifact Type Code: S
	CD(s) with content unspecified Doc Code: Artifact Type Code: U
	Microfilm(s) Doc Code: Artifact Type Code: F
	Video tape(s) Doc Code: Artifact Type Code: V
	Model(s) Doc Code: Artifact Artifact Type Code: M
	Bound Document(s) Doc Code: Artifact Type Code: B
V	Other, description: 6,060,384Z Doc Code: Artifact Type Code: Z

-SI AVAILABLE COPY

The Director of the United States Patent and Trademark Office Has received an application for a patent for a

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.

If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.

If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extensions.

Division of the United States Patent and Trademark Office

Mare Ilm





BEST AVAILABLE COI

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,060,284

DATED

: May 9, 2000

INVENTOR(S): J. Fernando Bazan

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 59, line 65, after "which" insert --encodes amino residues 155-164 of SEQ ID NO: 2 and --.

Column 60, line 53, delete "; and" and line 54 delete "c) encodes amino residues 155-164 of SEQ ID NO: 2."

Column 60, line 61, change "1" to --3--.

Column 62, line 7, insert "or".

Column 62, line 17, delete "is".



Signed and Sealed this

Twenty-sixth Day of September, 2000

Attesting Officer

Q. TODD DICKINSON

Director of Patents and Trademarks

BEST AVAILABLE BUTTON BANK

United States Patent [19]

Bazan

Patent Number: [11]

6,060,284

Date of Patent: [45]

May 9, 2000

[54] DNA ENCODING INTERLEUKIN-B30

Inventor: J. Fernando Bazan, Menlo Park, Calif.

Assignee: Schering Corporation, Kenilworth,

N.J.

[21] Appl. No.: 09/122,443

[22] Filed: Jul. 24, 1998

Related U.S. Application Data

Provisional application No. 60/053,765, Jul. 25, 1997.

Int. Cl.⁷ C12N 15/24; C12N 15/63; C12N 5/10; C07K 14/54

536/24.3; 536/24.31; 530/351; 435/70.1; 435/71.1; 435/71.2; 435/325; 435/471; 435/320.1; 435/252.3; 435/254.11

[58] Field of Search 536/23.1, 23.5, 536/24.3, 24.31; 530/351; 435/69.52, 704, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

[56] References Cited

PUBLICATIONS

Ito et al. Gen Bank Accession #AB004061, Jun.2, 1997. F.R. Blattner, et al., GenPept, Accession No. 2506659, Nov. 1, 1997. Definition: "Hypothetical 55.1 KD Protein In OGT-DBPA Intergenic Region.".

T.D. Gaffney, et al., GenPept, Accession No. 1172467, Nov. 1995. Definition: "CDP-Diacylglycerol-Glycerol-3-Phosphate 3-Phosphatidyltransferase (Phosophatidylglycerophosphate Synthase) (PGP Synthase).".

Toshio Hirano, The Cytokine Handbook, Angus W. Thompson, Editor, 2nd Ed., Ch. 8:145-168, Academic Press, San Diego, 1994. "Interleukin-6".

L. Hillier, et al., GenBank, Accession No. AA418955, Oct. 16, 1997. Definition: "zw01c10.rl Soares NhHMPu S1 Homo sapiens cDNA clone 768018 5'.".

Y. Ito, GenBank, Accession No. AB004061, Jun. 2, 1997. Definition: "domestic pig mRNA for STAT2, complete cds.".

Shigekazu Nagata, The Cytokine Handbook, Angus W. Thompson, Editor, 2nd Ed., Ch. 20:371-385-168, Academic Press, San Diego, 1994. "Granulocyte Colony Stimulating Factor and its Receptor".

W. Northemann, et al., GenPept, Accession No. 111880, Jun. 18, 1993. Definition: "interleukin-6 precursor-rat.".

W. Northemann et al., GenPept, Accession No. 124350, Jul. 15, 1998. Definition: "Interleukin-6 Precursor (IL-6)".

J. Takeda, GenBank, Accession No. C06368, Oct. 11, 1996. Definition: "similar to none".

M. Tsuchiya, et al., GenPept, Accession no. 117565, Jul. 15, 1998. Definition: "Granulocyte Colony-Stimulating Factor Precursor (G-CSF).".

M. Tsuchiya, et al., GenPep, Accession No. 90543, Jun. 7, 1996. Definition: "granulocyte colony-stimulating faactor precursor-mouse.".

J. Van Snick, et al., GenPept, Accession No. 124348, Jul. 15, 1998. Definition: "Interleukin-6 Precursor (IL-6) (interleukin HP-1) (B-Cell Hybridoma Growth Factor).".

J. Van Snick, et al., GenPept, Accession No. 69691, Jun. 7, 1996. Definition: "interleukin-6 precursor—mouse.".

Primary Examiner-Prema Mertz

Attorney, Agent, or Firm-Gerald P. Keleher; Edwin P. Ching

[57]

ABSTRACT

Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using the reagents and diagnostic kits are also provided.

17 Claims, No Drawings

was and the contract of the contract of the